Joseph M. Fox

Joseph M. Fox is a distinguished Professor in the Department of Chemistry and Biochemistry at the University of Delaware's College of Arts & Sciences. His research has had significant impact across chemical biology, medicine, nuclear medicine, and material science, with his tetrazine ligation reaction cited as essential to the 2022 Nobel Prizes in Chemistry.

Dr. Fox's educational background includes:

• A.B., 1993, Princeton University
• M.S., 1994, Columbia University
• Ph.D., 1998, Columbia University
• National Institutes of Health Postdoctoral Fellow, 1999–2001, Massachusetts Institute of Technology

Professor Fox's research centers on developing new chemical reactions, particularly in bioorthogonal chemistry. His laboratory pioneered the tetrazine ligation—the fastest known bioorthogonal reaction—and developed the only general method for synthesizing trans-cyclooctenes. His work spans organic synthesis methodology, applications in chemical biology, and materials science through active collaborations with groups in peptide chemistry, bioorganic chemistry, surface science, computational chemistry, and radioimaging.

Analysis of Professor Fox's recent publications reveals a strong focus on advancing bioorthogonal chemistry tools, particularly tetrazine-based reactions, with applications in live cell imaging, cancer research, tissue engineering, and drug delivery. His work increasingly integrates enzymatic and photochemical activation methods, demonstrating a trajectory toward more controlled and targeted biological applications.

Professor Fox has received numerous prestigious awards for his scientific contributions:

• National Academy of Inventors Fellow (2023)
• Francis Alison Award, University of Delaware's highest faculty honor (2023)
• Arthur Cope Scholar Award from the American Chemical Society
• Delaware Bioscience Association Award for Academic Research
• American Chemical Society Delaware Section Award

As an educator and mentor, Professor Fox has guided 29 graduate students to completion of their Ph.D. degrees, co-advised four additional students, and mentored over 40 undergraduates in research. He serves as principal investigator and director of the NIH-funded Center of Biomedical Research Excellence (COBRE) on Discovery of Chemical Probes and Therapeutic Leads, where he has mentored numerous early-career faculty. His six issued patents with two pending have been licensed to multiple companies, demonstrating significant translational impact of his research.

The Fox Research Group operates at the intersection of chemistry and biology, maintaining active collaborations across multiple disciplines. Their multidisciplinary approach combines synthetic organic chemistry with applications in biological imaging, therapeutic development, and materials science, creating a dynamic research environment focused on solving complex scientific challenges.